Survival of transplant recipients strongly depends on the success of the immunosuppressive regimen. Many immunosuppressive drugs such as calcineurin inhibitors (CNIs) and purine biosynthesis inhibitors (mycophenolic acids) are used after renal transplantation. Everolimus is a new agent which is a proliferation signal inhibitor (PSI)/mammalian target of rapamycin inhibitor that is structurally similar to sirolimus. Everolimus has adverse effects associated with dose-related class actions including proteinuria. Proteinuria due to sirolimus has been reported previously but there are only a few publications about everolimus. Here, we report a case with severe proteinuria due to everolimus which developed three months after transplantation.